Prospective antifungal therapy (PATH) alliance®: Focus on mucormycosis

Mycoses

Volumn 57, Issue 4, 2014, Pages 240-246

  Kontoyiannis, Dimitrios P ^a   Azie, Nkechi ^b   Franks, Billy ^b   Horn, David L ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c David Horn LLC   (United States)

Author keywords

Epidemiology; Mucormycosis; Survival; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CUNNINGHAMELLA; CYTOMEGALOVIRUS INFECTION; DEBRIDEMENT; DISEASE REGISTRY; FEMALE; FUNGUS ISOLATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LICHTHEIMIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MUCOR; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHIZOMUCOR; RHIZOPUS; SURGICAL DRAINAGE; SURVIVAL RATE; SYNCEPHALASTRUM;

MUCOR; RHIZOMUCOR; RHIZOPUS;

EPIDEMIOLOGY; MUCORMYCOSIS; PATH ALLIANCE®; SURVIVAL; TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCORALES; MUCORMYCOSIS; NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84895791493     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12149     Document Type: Article

References (16)

1. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006; 20: 581-607, vi.
2. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15: 1395-401.
3. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009; 15(Suppl. 5): S93-7.
4. Park BJ, Pappas PG, Wannemuehler KA et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17: 1855-64.
5. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-9.
6. Horn DL, Fishman JA, Steinbach WJ et al. Presentation of the PATH alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007; 59: 407-14.
7. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
8. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (prospective antifungal therapy) alliance(R) registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 2012; 73: 293-300.
9. Lanternier F, Dannaoui E, Morizot G et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis 2012; 54(Suppl. 1): S35-43.
10. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-67.
11. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
12. Dabritz J, Attarbaschi A, Tintelnot K et al. Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases. Mycoses 2011; 54: e785-8.
13. Auberger J, Lass-Flörl C, Aigner M, Clausen J, Gastl G, Nachbaur D. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother 2012; 67: 2268-73.
14. Skiada A, Lanternier F, Groll AH et al. Diagnosis and treatment of mucormycosis in patients with haematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013; 98: 492-504.
15. Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother 2011; 55: 5018-21.
16. Spellberg B, Kontoyiannis DP, Fredricks D et al. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012; 50: 611-8.